Astek Diagnostics GTM brain

category

market profile

• text: Conventional UTI care can involve empirical antibiotic selection while confirmatory testing takes days.
• text: Current development prioritizes urine; blood and other sample applications are future development, not established commercial offerings.

personas

• title: Urologist or point-of-care clinician
  pains:

  • Treats suspected UTI before susceptibility results are available
  • Needs actionable information while the patient is present
• title: Hospital laboratory or diagnostics director
  pains:

  • Must assess analytical performance and workflow integration
  • Needs a cost and operational case for adopting a new instrument
• title: Antimicrobial stewardship lead
  pains:

  • Wants to reduce unnecessary or ineffective antibiotic exposure
  • Needs evidence that earlier testing changes prescribing

icp

• text: US urology practices and care sites treating patients with suspected UTI are initial commercial targets.
• text: Hospital systems and research partners with UTI and antimicrobial stewardship priorities are potential pilot accounts.

message pillars

• text: Compress the time to actionable infection information.
• text: Link diagnosis with antibiotic sensitivity information.
• text: Tie precision diagnostics to treatment quality.

objections

• objection: Is the test cleared for routine clinical use?
  response: Verify current regulatory status, intended use and availability directly with Astek before any purchase; published plans are not clearance.
• objection: Can one-hour results fit our workflow and improve decisions?
  response: Request prospective validation, staffing requirements, antibiotic panel and a site-specific evaluation.
• objection: What is the economic case?
  response: Ask for instrument, consumable and reimbursement details and compare them with existing workflows.

competitors

• name: Sysmex Astrego
  why: Develops rapid UTI diagnostic and antibiotic susceptibility testing.
• name: Microplate Dx
  why: Develops rapid susceptibility testing for suspected UTI.
• name: InnotiveDx
  why: Develops a rapid urine diagnostic and susceptibility platform.

keywords

• rapid UTI test
• point of care antibiotic susceptibility testing
• urine culture alternative
• antimicrobial stewardship diagnostics
• one hour UTI diagnosis

voice

• Clinical and evidence-oriented
• Urgent about antibiotic resistance
• Patient-centered

signals

• text: A urology practice is evaluating faster UTI testing at the point of care.
• text: A hospital has an active antimicrobial stewardship or diagnostic pilot initiative.

stack

• Microfluidics

pricing

motion

channels

• clinical partnerships
• LinkedIn
• press

confidence

Founders

• name: Mustafa Al-Adhami
  title: Founder
  role: Founder
  bio: Mustafa Al-Adhami Ph.D., CEO, Astek Diagnostics. He has long experience in customer discovery and diagnostics. He envisioned the technology behind Eugris while completing his PhD. As a doctoral student, he won the national Three Minute Thesis (3mt) competition, Baylor Business Plan, elevator pitch competition, and VentureWell’s BMEidea competition. Mustafa has raised over $5M for Astek to date to revolutionize antibiotic prescription.